Compare RYTM & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | DUOL |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 2017 | 2021 |
| Metric | RYTM | DUOL |
|---|---|---|
| Price | $115.63 | $130.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 18 |
| Target Price | $131.14 | ★ $176.69 |
| AVG Volume (30 Days) | 640.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.34 | ★ 355.85 |
| EPS | N/A | ★ 1.53 |
| Revenue | N/A | ★ $1,037,589,000.00 |
| Revenue This Year | $55.34 | $18.93 |
| Revenue Next Year | $86.06 | $14.02 |
| P/E Ratio | ★ N/A | $80.12 |
| Revenue Growth | N/A | ★ 38.71 |
| 52 Week Low | $74.50 | $87.89 |
| 52 Week High | $122.20 | $373.50 |
| Indicator | RYTM | DUOL |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 44.04 |
| Support Level | $98.76 | $107.24 |
| Resistance Level | $113.03 | $138.41 |
| Average True Range (ATR) | 4.84 | 8.06 |
| MACD | 0.15 | -0.62 |
| Stochastic Oscillator | 98.64 | 33.23 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated, master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue: time-based subscriptions, in-app advertising placement by third parties, the Duolingo English Test, and In-App purchases. Geographically, the company generates revenue from its customers in the United States and other markets.